Skip to main content

Therapeutic Use Exemptions: Can WADA Strike A Fairer Balance Between Prospective & Retroactive Applications?

Cyclist with inhaler
Thursday, 27 October 2022 Author: Harry Bambury

Therapeutic use exemptions (TUEs) allow athletes who use medications or methods prohibited by the World Anti-Doping Agency (WADA) for the treatment of an illness or medical condition to continue to use these treatments without falling foul of anti-doping rules. The International Standard for Therapeutic Use Exemptions (ISTUE) sets out the rules concerning the grant of a TUE. The rules were most recently revised and approved by the WADA Executive Committee on 23 September 2022 and the latest version1 (analysed in this article) will be effective from 1 January 2023. The regime set out thereunder envisages both prospective (before testing) and retroactive (after testing) applications for a TUE, with the former representing the orthodoxy and the latter being available only where certain criteria are satisfied. This article will explore:

  • Whether the balance struck between prospective and retroactive TUEs is appropriate;

  • Whether retroactive TUEs are capable of playing a more significant role in anti-doping regimes; and

  • if so, whether the ISTUE should cast a wider retroactive TUE net.

To continue reading or watching login or register here

Already a member? Sign in

Get access to all of the expert analysis and commentary at LawInSport including articles, webinars, conference videos and podcast transcripts.  Find out more here.

Related Articles

Written by

Harry Bambury

Harry Bambury

Harry is a trainee solicitor at Mills & Reeve based in the firm’s Birmingham office. Harry has worked on a number of sports law matters, ranging from anti-doping cases to work permit applications for professional footballers. Before starting at Mills & Reeve, Harry studied jurisprudence at the University of Oxford.

  • This email address is being protected from spambots. You need JavaScript enabled to view it.